Back to Journals » Integrated Blood Pressure Control » Volume 6

Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination

Authors Hovater MB, Jaimes EA

Received 30 January 2013

Accepted for publication 8 April 2013

Published 14 June 2013 Volume 2013:6 Pages 59—67


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Michael B Hovater,1 Edgar A Jaimes1,2

1Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; 2Department of Veterans Affairs Medical Center, University of Alabama at Birmingham, Birmingham, AL, USA

Abstract: High blood pressure is the leading risk factor for death and disability worldwide, and the prevalence is increasing. Effective treatment decreases the risk of adverse events in proportion to blood pressure reduction. Combination antihypertensive therapy reduces blood pressure promptly and effectively. Single-pill combinations reduce the pill burden and improve adherence, efficacy, and tolerability of treatment compared with single drug pills. A significant portion of the hypertensive population will require three drugs for adequate control. The single-pill combination of aliskiren, amlodipine, and hydrochlorothiazide is based on complementary mechanisms of action. Clinical trials have shown it to be a safe and effective treatment for hypertension. This combination is a reasonable choice in clinical practice for patients with hypertension that requires three drugs for effective treatment.

Keywords: aliskiren, amlodipine, hydrochlorothiazide, Amturnide, hypertension, combination

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]